🔴 Nuvation Bio is trading 7.6% down in pre-market as investors weigh mixed results and outlook

Nuvation Bio is trading 7.6% lower at $4.37 following its November 4 earnings release, as investors weigh mixed results and outlook.

• Revenue reached $44.95 million, above analyst estimates; the reported loss was $0.12 per share, slightly worse than the $0.11 consensus cited by Zacks.
• IBTROZI product revenue grew 18% sequentially, while collaboration revenue contributed $17.5 million, including a milestone payment.